慢性心衰合并心律失常患者行胺碘酮治疗对心功能的影响以及安全性分析

Analysis of effects and safety of amiodarone on cardiac function in patients with chronic heart failure complicated with arrhythmia

目的研究胺碘酮治疗慢性心力衰竭(心衰)合并心律失常患者的安全性及对其心功能的影响。方法86例慢性心衰合并心律失常患者,采用随机数字表法分为科研组与参照组,每组43例。参照组患者采用厄贝沙坦治疗,科研组患者采用厄贝沙坦联合胺碘酮治疗。比较两组患者心功能指标、临床指标、临床疗效及不良反应发生情况。结果治疗后,科研组患者心率(76.82±16.35)次/min、舒张压(71.05±10.84)mm Hg(1 mm Hg=0.133 kPa)、收缩压(103.84±23.01)mm Hg均低于参照组的(84.27±15.21)次/min、(79.43±11.82)mm Hg、(115.39±22.84)mm Hg,心电图QT离散度(QTc)(412.65±31.19)ms高于参照组的(397.42±30.68)ms,差异具有统计学意义(P<0.05);科研组患者左心室舒张末期内径(LVEDD)(56.18±3.24)mm、左心室收缩末期内径(LVESD)(51.13±3.14)mm短于参照组的(60.01±3.17)、(55.06±3.01)mm,左室射血分数(LVEF)(50.39±1.26)%高于参照组的(45.61±0.87)%,差异具有统计学意义(P<0.05)。科研组患者总有效率97.67%高于参照组的83.72%,差异具有统计学意义(P<0.05)。科研组患者不良反应发生率9.30%低于参照组的25.58%,差异具有统计学意义(P<0.05)。结论胺碘酮治疗慢性心衰合并心律失常患者能提高临床疗效,改善心功能,控制疾病进展,且安全性高,值得临床推广应用。

Objective To investigate the effects and safety of amiodarone in the treatment of patients with chronic heart failure complicated with arrhythmia.Methods 86 patients with chronic heart failure complicated with arrhythmia were randomly divided into research group and control group,with 43 cases in each group.Patients in the control group were administrated with irbesartan,and patients in the research group were administrated with irbesartan combined with amiodarone.The cardiac function indicators,clinical indicators,clinical efficacy and incidence of adverse reactions were compared between the two groups.Results After the treatment,the research group had heart rate of(76.82±16.35)beats/min,diastolic blood pressure of(71.05±10.84)mm Hg(1 mm Hg=0.133 kPa),systolic blood pressure of(103.84±23.01)mm Hg,which were lower than(84.27±15.21)beats/min,(79.43±11.82)mm Hg,(115.39±22.84)mm Hg of the control group,respectively;ECG QT dispersion of the research group was(412.65±31.19)ms,which was higher than(397.42±30.68)ms of the control group;and the differences were statistically significant(P<0.05).The research group had left ventricular end diastolic diameter(LVEDd)of(56.18±3.24)mm,left ventricular end systolic diameter(LVESD)of(51.13±3.14)mm,which were shorter than(60.01±3.17)and(55.06±3.01)mm of the reference group,respectively;the left ventricular ejection fraction(LVEF)of the research group was(50.39±1.26)%,which was higher than(45.61±0.87)%of the control group;and the differences were statistically significant(P<0.05).The overall effective rate of the research group was 97.67%,which was higher than 83.72%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the research group was 9.30%,which was lower than 25.58%of the control group,and the difference was statistically significant(P<0.05).Conclusion Using amiodarone in patients with chronic heart failure complicated with arrhythmia may improve the overall effective rate,with improvement of cardiac function,control of disease progression and high safety.Hence,it is worthy of promotion in clinical practices.